885067-95-8

Usage

Uses

Used in Organic Synthesis:
(3-boronophenyl)dimethylacetonitrile is used as a reagent for the formation of carbon-carbon and carbon-nitrogen bonds in organic synthesis. Its unique reactivity and ability to interact with various functional groups make it a valuable tool in the synthesis of complex organic molecules.
Used in Materials Science:
(3-boronophenyl)dimethylacetonitrile is used as a building block in the development of new materials with unique properties. Its ability to form stable bonds with other molecules allows for the creation of materials with improved performance characteristics.
Used in Pharmaceutical Research:
(3-boronophenyl)dimethylacetonitrile is used as a starting material or intermediate in the synthesis of pharmaceutical compounds. Its unique properties and reactivity make it a promising candidate for the development of new drugs and therapeutic agents.
Used in Chemical Research and Development:
(3-boronophenyl)dimethylacetonitrile is used as a valuable tool in chemical research and development. Its ability to interact with various functional groups and its role as a building block in the synthesis of complex organic molecules make it an essential component in the advancement of chemical science.

Upstream product

• 90433-20-8 2-(3-bromo-phenyl)-2-methyl-propionitrile 

Relevant academic research and scientific papers

A COMBINATION OF NIACIN AND A PROSTAGLANDIN D2 RECEPTOR ANTAGONIST

The present invention is directed to a pharmaceutical composition comprising Niacin or a pharmaceutically acceptable salt, solvate or N-oxide thereof, or a nicotinic acid receptor agonist, and a compound of formula (I) as defined herein, or an N-oxide thereof, or an ester prodrug thereof, or a pharmaceutically acceptable salt, hydrate, or solvate thereof, and its use for treating atherosclerosis, dyslipidemia, diabetes or a related condition while reducing substantial flushing.

2, 6-SUBSTITUTED-4-MONOSUBSTITUTEDAMINO-PYRIDIMIDINE AS PROSTAGLANDIN D2 RECEPTOR ANTAGONISTS

The present invention is directed a compound of Formula (I) as defined herein, a pharmaceutical composition comprising a pharmaceutically effective amount of one or more compounds according to Formula (I) in admixture with a pharmaceutically acceptable carrier, and a method of treating a patient suffering from a PGD2-mediated disorder including, but not limited to, allergic disease (such as allergic rhinitis, allergic conjunctivitis, atopic dermatitis, bronchial asthma and food allergy), systemic mastocytosis, discorders accompanied by systemic mast cell activation, anaphylaxis shock, bronchoconstriction, bronchitis, urticaria, eczema, diseases accompanied by itch (such as atopic dermatitis and urticaria), diseases (such as cataract, retinal detachment, inflammation, infection and sleeping disorders) which is generated secondarily as a result of behavior accompanied by itch (such as scratching and beating), inflammation, chronic obstructive pulmonary diseases, ischemic reperfusion injury, cerebrovascular accident, chronic rheumatoid arthritis, pleurisy, ulcerative colitis and the like by administering to said patient a pharmaceutically effective amount of a compound according to Formula (I).